Showing results (171-180 of 207) with videos related to
Sort By:
Pageof 21
British Journal of Haematology|April 1, 2015
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patientsAnders Österborg, William G Wierda, Jiří Mayer, et al.Blood|August 26, 2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHLGerman Ott, Marita Ziepert, Wolfram Klapper, et al.Blood|November 5, 2016
Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantationDaniel Fuerst, Christine Neuchel, Dietger Niederwieser, et al.Leukemia|February 27, 2018
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saussele, Rüdiger Hehlmann, Alice Fabarius, et al.The Lancet. Oncology|January 30, 2008
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2017
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupAnnette M Staiger, Marita Ziepert, Heike Horn, et al.The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.Leukemia & Lymphoma|August 26, 2017
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYCUlrike Paul, Julia Richter, Christiane Stuhlmann-Laiesz, et al.Nature Communications|May 20, 2020
Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphomaLorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5Markus Sieber, Hans Tesch, Beate Pfistner, et al.Pageof 21